Survival by Response to First-line Platinum-Based Therapy Among Patients With Extensive Disease Small Cell Lung Cancer

被引：0
|
作者：
Danese, M. [1 ]
Gleeson, M. [1 ]
Lubeck, D. [1 ]
Penrod, J. [2 ]
Korytowsky, B. [2 ]
Yuan, Y. [2 ]
机构：
[1] Outcomes Insights Inc, Westlake Village, CA USA
[2] Bristol Myers Squibb, Princeton, NJ USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 11期
关键词：
small cell lung cancer; overall survival; platinum-based therapy;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1.15-003
引用
收藏
页码：S2043 / S2043
页数：1
相关论文
共 50 条
  • [41] AMRUBICIN (AMR) VS TOPOTECAN AS SECOND-LINE TREATMENT OF EXTENSIVE-DISEASE SMALL CELL LUNG CANCER (SCLC) SENSITIVE TO PLATINUM-BASED FIRST-LINE CHEMOTHERAPY: A RANDOMIZED PHASE 2 TRIAL
    Jotte, R. M.
    Reynolds, C.
    Conkling, P.
    Jungnelius, U.
    Oliver, J.
    ANNALS OF ONCOLOGY, 2008, 19 : 116 - 116
  • [42] Retrospective analysis of type of KRAS mutation (mut) and response to first-line platinum-based chemotherapy (PC) in non-small cell lung cancer (NSCLC) patients (pts)
    Mellema, Wouter Willem
    Masen-Poos, Lucie
    Hendriks, Lizza
    Van Der Wekken, Anthonie
    Aerts, Joachim
    Herder, Judith
    Stigt, Jos
    Van den Borne, Ben
    van den Heuvel, Michel M.
    Pouw, Ellen
    Dingemans, Anne-Marie C.
    Smit, Egbert F.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [43] Does Platinum-Based Chemotherapy Still Have a Role in First-Line Treatment of Advanced Non-Small-Cell Lung Cancer?
    Lisberg, Aaron
    Garon, Edward Brian
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07) : 529 - +
  • [44] Bevacizumab (Avastin) in Combination with Platinum-Based Chemotherapy as First-Line Therapy for Advanced Non-Small Cell Lung Cancer in Different Age Groups in Germany
    Wirtz, H.
    Lang, S.
    Gessner, C.
    Krueger, S.
    Zortel, M.
    Heinzmann, S.
    Schuette, W.
    PNEUMOLOGIE, 2020, 74 : S16 - S16
  • [45] Clinical and molecular features in patients with advanced non-small-cell lung carcinoma refractory to first-line platinum-based chemotherapy
    Leprieur, E. Giroux
    Antoine, M.
    Vieira, T.
    Duruisseaux, M.
    Poulot, V.
    Rabbe, N.
    Belmont, L.
    Gounant, V.
    Lavole, A.
    Milleron, B.
    Lacave, R.
    Cadranel, J.
    Wislez, M.
    LUNG CANCER, 2013, 79 (02) : 167 - 172
  • [46] First-line sintilimab combined with platinum-based chemotherapy in extensive stage small cell lung cancer: A phase II study and post-hoc biomarker analysis.
    Su, ChunXia
    Xie, Mengqing
    Zhao, Jing
    Chu, Xiangling
    Liu, Li
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [47] Results of a randomized phase II trial of amrubicin (AMR) versus topotecan (Topo) in patients with extensive-disease small cell lung cancer (ED-SCLC) sensitive to first-line platinum-based chemotherapy
    Jotte, R.
    Conkling, P.
    Reynolds, C.
    Klein, L.
    Fitzgibbons, J. F.
    McNally, R.
    Renschler, M.
    Oliver, J. W.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [48] Similar survival benefits of a good response and stable disease to platinum-based chemotherapy in non-small cell lung cancer
    Tamura, Tomohiro
    Kurishima, Koichi
    Nakazawa, Kensuke
    Ishikawa, Hiroichi
    Satoh, Hiroaki
    Hizawa, Nobuyuki
    ONCOLOGY LETTERS, 2015, 10 (02) : 1135 - 1140
  • [49] UPFRONT GENOMIC TESTING FOR PATIENTS WITH NON-SMALL CELL LUNG CANCER RECEIVING FIRST-LINE PLATINUM-BASED REGIMEN: PRELIMINARY RESULT OF THE MSN STUDY
    Planchard, D.
    Lueza, B.
    Rahal, A.
    Lacroix, L.
    Ngocamus, M.
    Auger, N.
    Saulnier, P.
    Dorfmuller, P.
    Le Chevalier, T.
    Celebic, A.
    Pignon, J. P.
    Soria, J. C.
    Besse, B.
    ANNALS OF ONCOLOGY, 2012, 23 : 13 - 13
  • [50] Thromboembolic events (TE) in patients with metastatic non small cell lung cancer (NSCLC) EGFR/ALK native treated with first-line platinum-based chemotherapy
    Castellon Rubio, V. E.
    Luque Caro, R.
    Gonzalez Flores, E.
    Canosa Ruiz, L.
    ANNALS OF ONCOLOGY, 2015, 26 : 116 - 116
12345